NCT03708653 is a clinical trial in Postherpetic Neuralgia, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT03708653?

NCT03708653 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT03708653 study?

NCT03708653 studies Postherpetic Neuralgia.

Is NCT03708653 still recruiting?

NCT03708653 is currently completed. Last updated 23 April 2019.

Last reviewed 2019-04-23 · How we verify

NCT03708653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single Nucleotide Polymorphisms (SNPs) Associated With Postherpetic Neuralgia

Completed Last updated 23 April 2019

What this trial tests

trial in Postherpetic Neuralgia in 181 participants. Completed in 13 February 2019.

Timeline

1 April 2018

Primary endpoint
13 February 2019

13 February 2019

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	181
Start date	1 April 2018
Primary completion	13 February 2019
Estimated completion	13 February 2019
Sites	1 location across China

Conditions studied

Postherpetic Neuralgia — all drugs for Postherpetic Neuralgia →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

50 and older, any sex, with Postherpetic Neuralgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postherpetic neuralgia (PHN) is a common condition and affecting 5 to 30% of the herpes zoster patients. In some cases, the pain remained refractory after first and second line treatment for herpes zoster. This suggests that there may be genetic variants that make some patients susceptible to PHN. Using saliva samples from herpes zoster patients the investigators are going to analyze the relationship between single nucleotide polymorphisms (SNPs) in genes that are known to be involved in pain and PHN.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03708653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 23 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03708653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing